17 alpha-hydroxylase deficiency screening: Difference between revisions
Jump to navigation
Jump to search
m (Mehrian.jafari moved page Congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency screening to 17 alpha-hydroxylase deficiency screening) |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ | {{17 alpha-hydroxylase deficiency}} | ||
{{CMG}}; {{AE}} {{ | {{CMG}}; {{AE}} {{MJ}} | ||
==Overview== | ==Overview== | ||
There is insufficient evidence to recommend routine screening for 11β-hydroxylase deficiency. | |||
==Screening== | ==Screening== | ||
There is insufficient evidence to recommend routine screening for 11β-hydroxylase deficiency. | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 15:34, 7 August 2017
|
17 alpha-hydroxylase deficiency Microchapters |
|
Differentiating 17 alpha-hydroxylase deficiency from other Diseases |
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
17 alpha-hydroxylase deficiency screening On the Web |
|
American Roentgen Ray Society Images of 17 alpha-hydroxylase deficiency screening |
|
Risk calculators and risk factors for 17 alpha-hydroxylase deficiency screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2]
Overview
There is insufficient evidence to recommend routine screening for 11β-hydroxylase deficiency.
Screening
There is insufficient evidence to recommend routine screening for 11β-hydroxylase deficiency.